IRX 2: Clinical Trials

5 trials of IRX 2, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 1 active not recruiting, 1 terminated. 5 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 25Completed 3, Active not recruiting 1, Terminated 1
Phase 11Completed 1

Follow IRX 2: new trials by email Literature Review of IRX 2 trials Research Report on IRX 2

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer
Pembrolizumab, IRX 2 - Breast Cancer, Breast Neoplasms
Phase 2Active not recruitingProvidence Health & Services122020-12-302026-04-24
IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer
Cyclophosphamide, Cytokine-based Biologic Agent IRX-2, Pembrolizumab - Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
Phase 1 / Phase 2CompletedCity of Hope Medical Center92019-04-302026-10-21
IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3
Cyclophosphamide, Indomethacin, IRX-2 - Cervical Squamous Cell Carcinoma In Situ, Vulvar High Grade Squamous Intraepithelial Lesion
Phase 2TerminatedUniversity of Southern California102017-11-082025-04-13
IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity
IRX-2, Cyclophosphamide, Indomethacin - Squamous Cell Carcinoma of the Oral Cavity
Phase 2CompletedBrooklyn ImmunoTherapeutics, LLC1052016-01-112024-01-30
A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer
IRX-2, Cyclophosphamide, Indomethacin - Squamous Cell Carcinoma of the Head and Neck
Phase 2CompletedBrooklyn ImmunoTherapeutics, LLC272005-07-012020-12-11

Conditions studied

Head and Neck Neoplasms (2)  ·  Squamous Cell Carcinoma of Head and Neck (2)  ·  Breast Neoplasms (1)  ·  Mouth Neoplasms (1)  ·  Neoplasms (1)  ·  Uterine Cervical Dysplasia (1)

Sponsors

Brooklyn ImmunoTherapeutics, LLC (2)  ·  City of Hope Medical Center (1)  ·  Providence Health & Services (1)  ·  University of Southern California (1)

Countries

United States (4)  ·  Brazil (1)  ·  Canada (1)  ·  United Kingdom (1)

Top investigators

Gregory T Wolf, MD, FACS (1)  ·  Jeffrey S. Moyer, MD (1)  ·  Joseph Chao (1)  ·  Lynda Roman, MD (1)

Results publications

PMID 20539208, PMID 21284052, PMID 22057678, PMID 22109700, PMID 32738599

NIH funding

P30CA014089 (1)